Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN versus CLINDAMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN versus CLINDAMYCIN HYDROCHLORIDE.
CLEOCIN vs CLINDAMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation.
Binds to the 50S ribosomal subunit, inhibiting peptide bond formation and bacterial protein synthesis.
150-450 mg orally every 6 hours; 300-600 mg IM or IV every 6-8 hours; maximum 4.8 g/day IV.
150-450 mg orally every 6 hours; maximum 1.8 g/day.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 8-12 hours in severe hepatic impairment; dialyzable but not clinically used for Clostridium difficile infection.
The terminal elimination half-life of clindamycin is approximately 2-3 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life is prolonged to 8-12 hours. Renal impairment does not significantly alter half-life.
Approximately 10% renal as active drug and metabolites, 90% fecal/biliary via enterohepatic circulation; <1% unchanged in urine.
Approximately 10-20% of clindamycin is excreted unchanged in urine; the remainder is hepatically metabolized and excreted in bile and feces as inactive metabolites. Fecal excretion accounts for about 4% of an administered dose as active drug and 60-70% as metabolites. Renal clearance is minor.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic